Posts Archive

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM The purpose of this study is to infuse BCMA CAR-NK 92 cells to...

(LUMMICAR STUDY 1) NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma...

NCT04155749: Phase 1: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma Master Protocol for the Phase 1 Study...

NCT04182581: Phase 1: A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma A Study of...

RRMM Phase A: Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with...

CARTITUDE-1 Ciltacabtagene Autoleucel autologous bi-epitope BCMA-targeted CAR T cells JNJ-68284528 LCAR-B38M cilta-cel The purpose of the...

EVOLVE Autologous BCMA-specific CAR-T cells JCARH125 NCT03430011: Phase 1/2 - Study Evaluating the Safety and Efficacy of JCARH125 in...

KarMMa-2 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk...

KarMMa-3 bb2121 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma...

NCT03672318: Phase 1: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma The body has different ways of fighting...

NCT03435796: Phase 2/3: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Long-Term Follow-up Protocol for...

NCT03752541: Efficacy and Safety Evaluation of BCMA-UCART AllogeneicT-cells with Anti-BCMA CAR Chimeric Antigen Receptor）in the Treatment...

The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells. CHINESE STUDY A...

NCT03716856: Phase 1 - Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma A single arm, open-label...

NCT03502577: Phase 1 - BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent...

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma This Phase I study will test the safety and anti-myeloma...

NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients...

CRB-402 Study of bb21217 in Multiple Myeloma Relapsed Refractory Multiple Myeloma RRMM Study CRB-402 is a 2-part, non-randomized, open...

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of LCAR-B38M CAR-T cells in...